6 hours ago
1
The study highlights Juncell Therapeutics' breakthroughs in TIL process development, demonstrating that its proprietary feeder-free system can generate robust, functional TILs from both "hot" and "cold" tumor tissues without relying on high-concentration interleukin-2 (IL-2). These TILs exhibited significant anti-tumor activity in syngeneic patient-derived organoid (PDO) and patient-derived xenograft (PDX) models. By eliminating IL-2 dependence and removing the need for feeder cells, the technology paves the way for safer TIL treatment regimens and reduces manufacturing costs.
Presentation Details:
Title: Development of A Feeder-Free Process for IL-2-Independent TIL Expansion
Poster Number: AMA362
Get the latest news
delivered to your inbox
Sign up for The Manila Times newsletters
By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.
Session: Thursday Poster Reception
Date and Time: May 15, 2025, 5:30 PM-7:00 PM
Location: Poster Hall Hall I2
About Juncell Therapeutics
Juncell Therapeutics is a biotech dedicated to developing high-quality, accessible IL-2 independent TIL therapies for the treatment of solid tumors. Juncell Therapeutics has established its proprietary DeepTIL® cell expansion and NovaGMP® gene modification technology platforms, which are designed to address the key challenges of conventional TIL therapies, making TILs "robust, competent, affordable, and accessible." Two clinical-stage TIL therapies have demonstrated promising safety and efficacy in the treatment of ten types of heavily pretreated advanced solid tumors, including lung cancer, triple-negative breast cancer, pancreatic cancer, high-grade glioma, ovarian cancer, endometrial cancer, cervical cancer, head and neck cancer, bile duct cancer and melanoma.
For more information, please visit:
https://www.linkedin.com/company/juncell-therapeutics
Juncell Contact:
